Selected research
Market Analysis & Forecast
Global Niraparib Market Analysis and Forecast 2026-2032
Market perspective
The global Niraparib market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Niraparib is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Europe market for Niraparib is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Read the full market overview
Asia-Pacific market for Niraparib is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The China market for Niraparib is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The major global manufacturers of Niraparib include TESARO and Everest Pharmaceuticals Limited etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Niraparib, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.
This report researches the key producers of Niraparib, also provides the sales of main regions and countries. Of the upcoming market potential for Niraparib, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Niraparib sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Niraparib market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Niraparib sales, projected growth trends, production technology, application and end-user industry.
Niraparib Segment by Company
TESARO
Everest Pharmaceuticals Limited
Niraparib Segment by Type
100mg*30 Capsules
100mg*60 Capsules
100mg*90 Capsules
Niraparib Segment by Application
Primary Peritoneal Cancer
Fallopian Tube Cancer
Recurrent Epithelial Ovarian Cancer
Others
Niraparib Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Niraparib market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Niraparib and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Niraparib.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Sales (consumption), revenue of Niraparib in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 4: Detailed analysis of Niraparib manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Niraparib sales, revenue, price, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.
Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.
Chapter 10: China type, by application, sales, and revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.
Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 14: The main concluding insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- 100mg*30 Capsules
- 100mg*60 Capsules
- 100mg*90 Capsules
Applications
- Primary Peritoneal Cancer
- Fallopian Tube Cancer
- Recurrent Epithelial Ovarian Cancer
- Others
Companies covered
- TESARO
- Everest Pharmaceuticals Limited
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Niraparib Market by Type
- 1.2.1 Global Niraparib Market Size by Type, 2021 VS 2025 VS 2032
- 1.2.2 100mg*30 Capsules
- 1.2.3 100mg*60 Capsules
- 1.2.4 100mg*90 Capsules
- 1.3 Niraparib Market by Application
- 1.3.1 Global Niraparib Market Size by Application, 2021 VS 2025 VS 2032
- 1.3.2 Primary Peritoneal Cancer
- 1.3.3 Fallopian Tube Cancer
- 1.3.4 Recurrent Epithelial Ovarian Cancer
- 1.3.5 Others
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 Niraparib Market Dynamics
- 2.1 Niraparib Industry Trends
- 2.2 Niraparib Industry Drivers
- 2.3 Niraparib Industry Opportunities and Challenges
- 2.4 Niraparib Industry Restraints
3 Global Market Growth Prospects
- 3.1 Global Niraparib Revenue Estimates and Forecasts (2021-2032)
- 3.2 Global Niraparib Revenue by Region
- 3.2.1 Global Niraparib Revenue by Region: 2021 VS 2025 VS 2032
- 3.2.2 Global Niraparib Revenue by Region (2021-2026)
- 3.2.3 Global Niraparib Revenue by Region (2027-2032)
- 3.2.4 Global Niraparib Revenue Market Share by Region (2021-2032)
- 3.3 Global Niraparib Sales Estimates and Forecasts 2021-2032
- 3.4 Global Niraparib Sales by Region
- 3.4.1 Global Niraparib Sales by Region: 2021 VS 2025 VS 2032
- 3.4.2 Global Niraparib Sales by Region (2021-2026)
- 3.4.3 Global Niraparib Sales by Region (2027-2032)
- 3.4.4 Global Niraparib Sales Market Share by Region (2021-2032)
- 3.5 US & Canada & Mexico
- 3.6 Europe
- 3.7 China
- 3.8 Asia (Excluding China)
- 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
- 4.1 Global Niraparib Revenue by Manufacturers
- 4.1.1 Global Niraparib Revenue by Manufacturers (2021-2026)
- 4.1.2 Global Niraparib Revenue Market Share by Manufacturers (2021-2026)
- 4.1.3 Global Niraparib Manufacturers Revenue Share Top 10 and Top 5 in 2025
- 4.2 Global Niraparib Sales by Manufacturers
- 4.2.1 Global Niraparib Sales by Manufacturers (2021-2026)
- 4.2.2 Global Niraparib Sales Market Share by Manufacturers (2021-2026)
- 4.2.3 Global Niraparib Manufacturers Sales Share Top 10 and Top 5 in 2025
- 4.3 Global Niraparib Sales Price by Manufacturers (2021-2026)
- 4.4 Global Niraparib Key Manufacturers Ranking, 2024 VS 2025 VS 2026
- 4.5 Global Niraparib Key Manufacturers Manufacturing Sites & Headquarters
- 4.6 Global Niraparib Manufacturers, Product Type & Application
- 4.7 Global Niraparib Manufacturers' Establishment Date
- 4.8 Market Competitive Analysis
- 4.8.1 Global Niraparib Market CR5 and HHI
- 4.8.2 2025 Niraparib Tier 1, Tier 2, and Tier 3
5 Niraparib Market by Type
- 5.1 Global Niraparib Revenue by Type
- 5.1.1 Global Niraparib Revenue by Type (2021 VS 2025 VS 2032)
- 5.1.2 Global Niraparib Revenue by Type (2021-2032) & (US$ Million)
- 5.1.3 Global Niraparib Revenue Market Share by Type (2021-2032)
- 5.2 Global Niraparib Sales by Type
- 5.2.1 Global Niraparib Sales by Type (2021 VS 2025 VS 2032)
- 5.2.2 Global Niraparib Sales by Type (2021-2032) & (k pcs)
- 5.2.3 Global Niraparib Sales Market Share by Type (2021-2032)
- 5.3 Global Niraparib Price by Type
6 Niraparib Market by Application
- 6.1 Global Niraparib Revenue by Application
- 6.1.1 Global Niraparib Revenue by Application (2021 VS 2025 VS 2032)
- 6.1.2 Global Niraparib Revenue by Application (2021-2032) & (US$ Million)
- 6.1.3 Global Niraparib Revenue Market Share by Application (2021-2032)
- 6.2 Global Niraparib Sales by Application
- 6.2.1 Global Niraparib Sales by Application (2021 VS 2025 VS 2032)
- 6.2.2 Global Niraparib Sales by Application (2021-2032) & (k pcs)
- 6.2.3 Global Niraparib Sales Market Share by Application (2021-2032)
- 6.3 Global Niraparib Price by Application
7 Company Profiles
- 7.1 TESARO
- 7.1.1 TESARO Company Information
- 7.1.2 TESARO Business Overview
- 7.1.3 TESARO Niraparib Sales, Revenue, Price and Gross Margin (2021-2026)
- 7.1.4 TESARO Niraparib Product Portfolio
- 7.1.5 TESARO Recent Developments
- 7.2 Everest Pharmaceuticals Limited
- 7.2.1 Everest Pharmaceuticals Limited Company Information
- 7.2.2 Everest Pharmaceuticals Limited Business Overview
- 7.2.3 Everest Pharmaceuticals Limited Niraparib Sales, Revenue, Price and Gross Margin (2021-2026)
- 7.2.4 Everest Pharmaceuticals Limited Niraparib Product Portfolio
- 7.2.5 Everest Pharmaceuticals Limited Recent Developments
8 North America
- 8.1 North America Niraparib Market Size by Type
- 8.1.1 North America Niraparib Revenue by Type (2021-2032)
- 8.1.2 North America Niraparib Sales by Type (2021-2032)
- 8.1.3 North America Niraparib Price by Type (2021-2032)
- 8.2 North America Niraparib Market Size by Application
- 8.2.1 North America Niraparib Revenue by Application (2021-2032)
- 8.2.2 North America Niraparib Sales by Application (2021-2032)
- 8.2.3 North America Niraparib Price by Application (2021-2032)
- 8.3 North America Niraparib Market Size by Country
- 8.3.1 North America Niraparib Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
- 8.3.2 North America Niraparib Sales by Country (2021 VS 2025 VS 2032)
- 8.3.3 North America Niraparib Price by Country (2021-2032)
- 8.3.4 United States
- 8.3.5 Canada
- 8.3.6 Mexico
9 Europe
- 9.1 Europe Niraparib Market Size by Type
- 9.1.1 Europe Niraparib Revenue by Type (2021-2032)
- 9.1.2 Europe Niraparib Sales by Type (2021-2032)
- 9.1.3 Europe Niraparib Price by Type (2021-2032)
- 9.2 Europe Niraparib Market Size by Application
- 9.2.1 Europe Niraparib Revenue by Application (2021-2032)
- 9.2.2 Europe Niraparib Sales by Application (2021-2032)
- 9.2.3 Europe Niraparib Price by Application (2021-2032)
- 9.3 Europe Niraparib Market Size by Country
- 9.3.1 Europe Niraparib Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
- 9.3.2 Europe Niraparib Sales by Country (2021 VS 2025 VS 2032)
- 9.3.3 Europe Niraparib Price by Country (2021-2032)
- 9.3.4 Germany
- 9.3.5 France
- 9.3.6 U.K.
- 9.3.7 Italy
- 9.3.8 Russia
- 9.3.9 Spain
- 9.3.10 Netherlands
10 China
- 10.1 China Niraparib Market Size by Type
- 10.1.1 China Niraparib Revenue by Type (2021-2032)
- 10.1.2 China Niraparib Sales by Type (2021-2032)
- 10.1.3 China Niraparib Price by Type (2021-2032)
- 10.2 China Niraparib Market Size by Application
- 10.2.1 China Niraparib Revenue by Application (2021-2032)
- 10.2.2 China Niraparib Sales by Application (2021-2032)
- 10.2.3 China Niraparib Price by Application (2021-2032)
11 Asia (Excluding China)
- 11.1 Asia Niraparib Market Size by Type
- 11.1.1 Asia Niraparib Revenue by Type (2021-2032)
- 11.1.2 Asia Niraparib Sales by Type (2021-2032)
- 11.1.3 Asia Niraparib Price by Type (2021-2032)
- 11.2 Asia Niraparib Market Size by Application
- 11.2.1 Asia Niraparib Revenue by Application (2021-2032)
- 11.2.2 Asia Niraparib Sales by Application (2021-2032)
- 11.2.3 Asia Niraparib Price by Application (2021-2032)
- 11.3 Asia Niraparib Market Size by Country
- 11.3.1 Asia Niraparib Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
- 11.3.2 Asia Niraparib Sales by Country (2021 VS 2025 VS 2032)
- 11.3.3 Asia Niraparib Price by Country (2021-2032)
- 11.3.4 Japan
- 11.3.5 South Korea
- 11.3.6 India
- 11.3.7 Australia
- 11.3.8 Taiwan
- 11.3.9 Southeast Asia
12 South America, Middle East and Africa
- 12.1 SAMEA Niraparib Market Size by Type
- 12.1.1 SAMEA Niraparib Revenue by Type (2021-2032)
- 12.1.2 SAMEA Niraparib Sales by Type (2021-2032)
- 12.1.3 SAMEA Niraparib Price by Type (2021-2032)
- 12.2 SAMEA Niraparib Market Size by Application
- 12.2.1 SAMEA Niraparib Revenue by Application (2021-2032)
- 12.2.2 SAMEA Niraparib Sales by Application (2021-2032)
- 12.2.3 SAMEA Niraparib Price by Application (2021-2032)
- 12.3 SAMEA Niraparib Market Size by Country
- 12.3.1 SAMEA Niraparib Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
- 12.3.2 SAMEA Niraparib Sales by Country (2021 VS 2025 VS 2032)
- 12.3.3 SAMEA Niraparib Price by Country (2021-2032)
- 12.3.4 Brazil
- 12.3.5 Argentina
- 12.3.6 Chile
- 12.3.7 Colombia
- 12.3.8 Peru
- 12.3.9 Saudi Arabia
- 12.3.10 Israel
- 12.3.11 UAE
- 12.3.12 Turkey
- 12.3.13 Iran
- 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
- 13.1 Niraparib Value Chain Analysis
- 13.1.1 Niraparib Key Raw Materials
- 13.1.2 Raw Materials Key Suppliers
- 13.1.3 Manufacturing Cost Structure
- 13.1.4 Niraparib Production Mode & Process
- 13.2 Niraparib Sales Channels Analysis
- 13.2.1 Direct Comparison with Distribution Share
- 13.2.2 Niraparib Distributors
- 13.2.3 Niraparib Customers
14 Concluding Insights
15 Appendix
- 15.1 Reasons for Doing This Study
- 15.2 Research Methodology
- 15.3 Research Process
- 15.4 Authors List of This Report
- 15.5 Data Source
- 15.5.1 Secondary Sources
- 15.5.2 Primary Sources
- 15.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst